Unfortunately, some therapies required to cure or control the cancer are cardiotoxic. This can lead to subclinical and clinical heart failure (HF) in patients with or without underlying cardiac risk factors. Cancer therapeutics related cardiac dysfunction (CTRCD) might lead to interruption or alteration of cancer therapy. Some patients can present weeks and years after treatment.
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.